Sofinnova Partners’ Post

Curious about Sofinnova AI, our internal AI platform? One year out of ‘stealth’ we at Sofinnova Partners can’t remember life without it. Over the coming weeks, we'll give you a peek into Sofinnova AI, think prompts and responses that are transforming our investment approach. 

« Wise » indeed ! Bravo Sofinnova

Thomas Wirth

Investor & Biotech executive

2mo

So fascinating. In particular, as I am currently studying the role of intuition in the decision-making processes within pharma and biotech companies. I believe AI is a powerful tool and will add great value. Obviously, one of its great advantages is removing bias from data analysis, thus, overall reducing bias from an investment decision. However, I am wondering how we can ensure the quality / validity of data that is being considered in the first place ? (I am referring to a Nature article published in December 2023, that states that more than 10,000 research papers were retracted in 2023 alone) Also, how AI will deal with contradicting information that has been published? In addition, what about those innovations where little (if any) pre-existing data exists? I believe that in those instances as well as when assessing the qualitative aspects of a team within an organization, its leadership or its culture, expert intuition may be powerful and add value to the decision making process.

Juhani Lahdenperä

AI & Biotech Strategist (eMBA) | M.Sc. in Molecular Biology | Biotech CEO & Chairman | Pharma Business Development | Life Science Investment Evaluator

2mo

Interesting approach! My tools or rather Agents, focuses on preparing companies for due diligence by refining communications, business plans, and evaluating VDR contents to ensure readiness. It sounds like your AI tool tackles the other side, supporting the evaluation process itself. A complementary angle—screening decks and opportunities must add significant value before entering due diligence! Would be happy to chat more of this topic sometime.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics